PCSK9 and metabolic syndrome: Many current lipid-lowering drugs upregulate LDL-R by stimulating SREBP-2, leading to PCSK9-mediated drug resistance in dyslipidemia, which can be regarded as a useful adjunct to statin therapy (Figure 1).